Department of Immunology 2nd Faculty of Medicine Charles University Prague and University Hospital in Motol 5 Uvalu 84 Prague 15006 Czech Republic

Department of Immunology and Allergology Faculty of Medicine and Faculty Hospital in Pilsen Charles University Prague Pilsen Czech Republic

Department of Pediatrics 1st Faculty of Medicine Charles University Prague and Thomayer University Hospital Prague Czech Republic

Zobrazit více v PubMed

Toubiana J, Okada S, Hiller J, Oleastro M, Gomez ML, Becerra JCA, Ouachée-Chardin M, Fouyssac F, Girisha KM, Etzioni A, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127:3154–3164. doi: 10.1182/blood-2015-11-679902. PubMed DOI PMC

Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, Al Shehri T, Abinun M, Gennery AR, Mann J, Lendrem DW, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC) Eur J Immunol. 2015;45:2834–2846. doi: 10.1002/eji.201445344. PubMed DOI

Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, Plant AS, Su HC, Allenspach EJ, Slatter M, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142. 10.1016/j.jaci.2018.07.020. PubMed PMC

Lim Y, Ng Y, Tam J, Liu D. Human coronaviruses: a review of virus–host interactions. Diseases. 2016;4. 10.3390/diseases4030026. PubMed PMC

Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180. 10.1016/j.cell.2020.02.041. PubMed PMC

Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zhang YG, Chang HY. Type i interferons: distinct biological activities and current applications for viral infection. Cell Physiol Biochem. 2018;51. 10.1159/000495897. PubMed

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80- ). 2020;370. 10.1126/science.abd4585. PubMed PMC

Zhang Q, Liu Z, Moncada-Velez M, Chen J, Ogishi M, Bigio B, Yang R, Arias AA, Zhou Q, Han JE, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (80- ). 2020;370. 10.1126/science.abd4570. PubMed PMC

Jirjees F, Saad AK, Al Hano Z, Hatahet T, Al Obaidi H, Dallal Bashi YH. COVID-19 treatment guidelines: do they really reflect best medical practices to manage the pandemic? Infect Dis Rep. 2021;13:259–284. doi: 10.3390/idr13020029. PubMed DOI PMC

Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020;28:455–464.e2. doi: 10.1016/j.chom.2020.07.005. PubMed DOI PMC

Guisado Hernández P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martín Gutierrez G, Castro MJ, Gutiérrez Valencia A, Sánchez Codez MI, Gaboli M, et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021;1–5. 10.1007/s10875-021-01081-9. PubMed PMC

Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, Lopez-Granados E, Gianelli C, Robles-Marhuenda A, Jeandel P-Y, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147:520–531. doi: 10.1016/j.jaci.2020.09.010. PubMed DOI PMC

Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, Tezcan I. COVID-19 in patients with primary immunodeficiency. J Clin Immunol. 2021 doi: 10.1007/s10875-021-01065-9. PubMed DOI PMC

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. PubMed DOI PMC

Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, Levi I, Benor S, Alcalay Y, Freund NT. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148:739–749. doi: 10.1016/j.jaci.2021.05.029. PubMed DOI PMC

Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, Keller MD, McDermott DH, Rao VK, Dimitrova D, Quiros-Roldan E, Imberti L, Ferrè EMN, Schmitt M, Lafeer C, Pfister J, Shaw D, Draper D, Truong M, Ulrick J, DiMaggio T, Urban A, FA. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021; 4:0091-6749(21)01356–7. PubMed PMC

Delphine S, Alexis M, Makoto M, Audrey M, François A, Laetitia C, Paul Q, Jehane F, Hervé D, Pascale G, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13:abd2223. doi: 10.1126/scitranslmed.abd2223. PubMed DOI PMC

Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;annrheumdis-2021-220781. 10.1136/annrheumdis-2021-220781. PubMed